This article is more than 5 years old. Information may no longer be current.

Iluvien delays recurrence of noninfectious posterior uveitis over 3 years

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Three-year data for Iluvien found a single implant delayed recurrence of noninfectious posterior uveitis and reduced uveitis symptoms, according to a press release from Alimera Sciences.

The phase 3 clinical trial showed the median time to first recurrence of noninfectious uveitis affecting the posterior of the eye was 657 days, or 94 weeks, in patients treated with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) compared with 70.5 days, or 10 weeks, in those treated with sham (P < .001). In addition, the Iluvien arm saw 1.7 uveitis recurrences compared with 5.3 in the sham arm over 36 months (P < .001), the release said.

“We are very pleased that Iluvien’s continuous microdosing technology not only reduces the recurrence of diabetic macular edema but can provide important and sustained benefits in patients diagnosed with noninfectious posterior uveitis,” Rick Eiswirth, president and CEO of Alimera, said in the release.

The European launch of Iluvien for noninfectious posterior uveitis is planned for the second half of this year.